Clenoliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD4 |
| Identifiers | |
| ATC code | None |
| ChemSpider | none |
  (what is this?) (verify) | |
Clenoliximab (INN[1]) is a monoclonal antibody against CD4. It acts as an immunomodulator and has been investigated for the treatment of rheumatoid arthritis.[2] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[1]
References
- 1 2 World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information 11 (2): 89.
- ↑ Hepburn, TW; Totoritis, MC; Davis, CB (2003). "Antibody-mediated stripping of CD4 from lymphocyte cell surface in patients with rheumatoid arthritis.". Rheumatology (Oxford, England) 42 (1): 54–61. doi:10.1093/rheumatology/keg030. PMID 12509613.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.